Kodiak Sciences Inc.
kodiak.comWhat Do They Do?
Develops investigational medicines for retinal diseases, including retinal vascular diseases and macular edema caused by inflammation.
10-K for FY2025, filed Mar 31, 2026Since its founding in 2009, Kodiak Sciences Inc. (“Kodiak,” the “Company,” “we” or “our”) has developed a new technology platform, the…View ↗
Kodiak’s second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC…View ↗
Kodiak’s third investigational medicine, KSI-101, is a high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$65.6MView ↗
- ▲ +21% (Loss)
- vs −$54.3M in Q2 FY2025
VETi’s intended uses
The older report describes VETi for eye care and health monitoring; the latest also names identity security and cognitive sciences as potential uses.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 31, 2026We are developing a visual engagement technology and imager (“VETi”) designed by Kodiak engineers initially to be used by eye care…View ↗
Our VETi (Visual Engagement Technology and imager) program has achieved significant advancements in hardware, software and algorithms…View ↗
Who Do They Compete With?
Competes with Regeneron
10-K for FY2025, filed Mar 31, 2026Regeneron’s Eylea HD is a major competitive product, with FDA approvals across wet AMD, DME, DR and RVO. In Phase 3 trials, Eylea HD…View ↗
Loading...
